Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

FDA Clears IND Application for NST-628

April 9, 2024

Clearance Received to Initiate R/R AML Trial With Lomonitinib

April 9, 2024

Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced

April 9, 2024

Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL

April 9, 2024

Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML

April 2, 2024

Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML

April 2, 2024

First Participant dosed in Ph 3 Study (Neoshot) of IBI310 + Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

April 2, 2024

First Patient Dosed in Ph 1/2a Trial of IMM-6-415 in Advanced Solid Tumors with RAF/RAS Mutations

April 2, 2024

First Patient Dosed in Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C+ve Solid Tumors

April 2, 2024

Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed

April 2, 2024

First Patient dosed in Clinical Study of the Combination of ICP-189 and Furmonertinib

April 2, 2024

Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced

April 2, 2024

Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study

April 2, 2024

Progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia reported

April 2, 2024

ARYA-3 Clinical Trial Advances to Ph 2 for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS T-cell Therapy

March 26, 2024

First patient dosed in Ph 1b/2 trial of LB-100 + dostarlimab-gxly in ovarian clear cell carcinoma

March 26, 2024

Enrollment Completed for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with R/R PCNSL

March 26, 2024

Lacutamab monotherapy development in PTCL to be discontinued after the anti-KIR3DL2 antibody fell short in Ph Ib trial

March 26, 2024

Ph 1 study of MGC026, topoisomerase I inhibitor-based ADC, initiated

March 18, 2024

U.S. FDA Lifts Partial Clinical Hold on NX-2127 Ph 1 Trial

March 18, 2024

Second Clinical Site for STAR-101 Ph 1 Trial opened

March 12, 2024

First Patient Dosed in Randomized First-line RAS-mutated mCRC Trial (CRDF-004)

March 12, 2024

First Patient dosed in Ph 1/2 study of IPH6501 in R/R B-Cell NHL

March 12, 2024

Patient Recruitment completed for the Ph 2a Trial of MaaT013 + Immune Checkpoint Inhibitors in Metastatic Melanoma

March 12, 2024

Debio0123 Monotherapy trial expanded In Gynecological Cancers And Other Biomarker-Driven Solid Tumors

March 12, 2024
Page1 … Page11 Page12 Page13 Page14 Page15 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.